jRCT2080220530未知1 期
A Phase I, Open-Label, Dose-Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4877 Administered Weekly in Japanese Adult Patients With Advanced Solid Malignancies
试验速览
- 阶段
- 1 期
- 发起方
- AstraZeneca
- 主要终点
- safety
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 干预模型
- Non-Randomized, Open Label, Uncontrolled, Single Group Assignment Study
入排标准
- 年龄范围
- 20age old over 至 75age old under（—）
- 性别
- All
入选标准
- •Ages Eligible for Study: 20 Years to 75 Years
- •Genders Eligible for Study: Both
- •Accepts Healthy Volunteers: No
- •Inclusion Criteria:
- •Patients diagnosed with solid tumour but which have no standard treatment or did not respond to previous treatments.
- •Patients who usually have mild symptoms capable of walking and light and sedentary work.
- •Patients who can stay in hospital at least during 4 weeks.
- •Exclusion Criteria:
- •Patients who have received treatment with anti-cancer agent within 4 weeks prior to first dose of study treatment; 6 weeks if the anti-cancer agent is mitomycin.
- •Patients with abnormally low levels of neutrophil count, platelet count, or haemoglobin, indicators of bone marrow function.
- •Patients who received therapeutic radiotherapy at central nervous system within 3 months prior to first dose of study treatment; the other sites within 4 weeks; or local site within 2 weeks.
排除标准
- 未提供
结局指标
主要结局
safety
To evaluate the safety of AZD4877 on a weekly schedule in Japanese patients with advanced solid malignancies
tolerability
To evaluate the tolerability of AZD4877 on a weekly schedule in Japanese patients with advanced solid malignancies
次要结局
未报告次要终点
研究者
相似试验
未知
1 期
A Phase I, Open-Label, Dose-Escalation Study to Assess the Safety and Tolerability of AZD0530 in Patients With Advanced Solid MalignanciesjRCT2080220617AstraZeneca
未知
1 期
A Phase I, Open-Label, Dose-Escalation Study to Assess the Safety and Tolerability of AZD0530 in Patients With Advanced Solid Malignanciesadvanced solid malignanciesJPRN-jRCT2080220617AstraZeneca
未知
1 期
A Phase I, Open-Label, Dose-Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4877 Administered Weekly in Japanese Adult Patients With Advanced Solid MalignanciesCancer, Tumors, CarcinomaJPRN-jRCT2080220530AstraZeneca
未知
1 期
A Phase 1, Open-Label, Dose-Escalation Study to Assess Safety, Tolerability & Pharmacokinetics of AZD7762 Administered as a Single Intravenous Agent and in Combination w/ Wkly Standard Dose Gemcitabine in Japanese Patients w/ Advanced Solid MalignanciesJPRN-jRCT2080220802AstraZeneca45
未知
1 期
A Phase 1, Open-Label, Dose-Escalation Study to Assess Safety, Tolerability & Pharmacokinetics of AZD7762 Administered as a Single Intravenous Agent and in Combination w/ Wkly Standard Dose Gemcitabine in Japanese Patients w/ Advanced Solid MalignanciesjRCT2080220802AstraZeneca45